mallia Aesthetics Spotlights SCD83 Hair Growth Approach at Hairs’25 Symposium
Augsburg, Germany – Mallia Aesthetics is showcasing its innovative SCD83-based approach to hair growth stimulation at the 24th International Symposium for Hair Science (hairs’25), taking place from June 25th to 27th, 2025.Prof. alexander Steinkasserer, co-founder of Mallia, presented the scientific results demonstrating SCD83’s potential to increase hair density [[1]].
Mallia Aesthetics, a gold sponsor of Hairs’25, is focused on developing adn marketing cosmetic products that stimulate hair growth.The symposium,organized by the German Society for scientific and Applied Cosmetics (DGK e.V.), brings together academic researchers and hair care industry experts.
SCD83: A Novel Therapeutic Approach for Alopecia
Prof. Steinkasserer’s lecture, titled “Soluble CD83 AS A Novel Therapeutic approach for the Treatment of Alopecia,” highlighted the multimodal mechanism of action of SCD83. Research indicates that SCD83 creates an anti-inflammatory environment in the hair follicle, inhibits cell death, and directly stimulates follicular stem cells.These combined effects promote new hair growth and increased hair density [[2]].
SCD83, initially identified as an immune-modulating molecule almost 25 years ago, has demonstrated therapeutic potential in skincare, wound healing, and hair growth. A recently preserved European patent covers both cosmetic and therapeutic applications of the molecule.
Did You Know? Alopecia affects over 70% of men and 50% of post-menopausal women worldwide.
Mallia’s Cosmetic Development and Future Products
Mallia Aesthetics is developing several cosmetic products leveraging SCD83 to stimulate hair growth. The company anticipates launching its first commercial product before the end of 2025.
According to Prof. Dr.Steinkasserer, “Our presentation at Hairs’25 and participation as a gold sponsor offer us a unique chance to present our innovative, science-based approach to a highly specialized audience. Our preclinical results clearly show an increase in hair growth and hair thickness. Moreover, we were able to decrypt in detail molecular signal paths and the multimodal mechanism of action of SCD83. I look forward to presenting our extensive and convincing data to this group of experts.”
The Science Behind SCD83
Soluble CD83 (SCD83) is an immune-modulating protein being developed for topical treatment of hair loss (MAL-856) and stimulation of hair growth (MAL-838).Discovered in 2001 by Prof. Dr. Steinkasserer, SCD83 exhibits anti-inflammatory properties, promotes wound healing, and supports new hair growth [[3]]. It also activates regulatory T cells (Tregs) that interact with and activate hair follicles.SCD83 inhibits hair follicle cell death and directly activates follicular stem cells, leading to new hair growth. This multimodal action differentiates SCD83 from other topical hair growth agents.
Topical application of SCD83 delivers the protein directly to the hair follicles without systemic absorption,minimizing potential side effects.
Hair Loss: A Global Concern
Androgenetic alopecia (AGA),or hormonal hair loss,is the most prevalent form of hair loss,affecting over 70% of men and 50% of women beyond menopause worldwide. Additionally, approximately 147 million people suffer from immune-related, circular hair loss (Alopecia areata or AA) [[4]].
AGA typically progresses gradually, influenced by genetic and hormonal factors. In men, it often leads to receding hairlines and baldness on the top of the head, while in women, it manifests as hair thinning in the apex area.Alopecia Areata causes circular hair loss on the scalp, face, or other body parts due to the immune system attacking hair follicles.
Mallia: Innovating in Hair Growth and Dermatology
Mallia Innovations GmbH, based in Erlangen, Germany, strategically drives the development and marketing of biopharmaceutical therapies and cosmetic applications based on the immune-modulating protein SCD83. The company focuses on hair growth, hair loss, wound healing, and other dermatological applications.
Mallia Therapeutics GmbH concentrates on clinical development of new therapies for patients suffering from AGA or AA, utilizing the scientifically proven immune-modulating action of SCD83.Mallia Aesthetics GmbH develops cosmetic products to stimulate hair growth, also based on the SCD83 protein.
| key Component | Description |
|---|---|
| SCD83 | Immune-modulating protein promoting hair growth. |
| Hairs’25 | 24th International Symposium for Hair Science. |
| Alopecia | Hair loss condition affecting millions worldwide. |
| Mallia Aesthetics | Company developing SCD83-based cosmetic products. |
Pro Tip: Maintaining a healthy diet and managing stress can also contribute to hair health.
What are your biggest concerns about hair loss, and what solutions have you explored?
How important is scientific backing when choosing hair growth products?
Understanding Hair Loss: An evergreen Perspective
Hair loss is a common concern with a complex interplay of genetic, hormonal, and environmental factors. While aging is a natural contributor,conditions like androgenetic alopecia and alopecia areata can significantly impact individuals of all ages. The development of novel treatments like SCD83 represents a promising avenue for addressing hair loss by targeting the underlying biological mechanisms. Continued research into the immune system’s role in hair follicle health is crucial for creating effective and safe therapies.
